Advertisement
"Among carbapenem antibiotics Merck's Primaxin/Tienam(imipenem/cilastatin) has the largest share of courses (54 percent), followedby AstraZeneca's Merrem/Meronem (meropenem) (36 percent) and Merck's Invanz(ertapenem injectable) (10 percent)," stated Joyce Wedemeyer, product directorat AMR. "These shares are consistent with our prior audit for the January --June 2007 time period."
Advertisement
The newly released European edition of The Hospital Antibiotic MarketGuide also finds that just over one-third of all carbapenem courses are usedas documented/confirmed therapy. Inpatients treated with a carbapenem coursein a documented/confirmed case are most commonly associated with escherichiacoli (29 percent of documented courses), pseudomonas aeruginosa (20 percent),methicillin-sensitive staphylococcus aureus (9 percent) and enterococcusfaecalis (8 percent).
Why Pharmaceutical Companies Need this Information
The Hospital Antibiotic Market Guide enables pharmaceutical companies tomonitor patient shares, costs, infectious disease prevalence and the clinicaluse of antibiotics in acute care hospitals. In addition, pathogen-leveldetails are available for those inpatient antibiotic drug courses associatedwith positive microbiological culture results.
About The Hospital Antibiotic Market Guide
The Hospital Antibiotic Market Guide is the industry's most comprehensiveaudit of inpatient antibiotic usage covering acute care hospitals in theUnited States, Italy, Germany, France, U.K. and Spain. The information in theaudit is abstracted directly from hospital source documents from a panel ofdemographically representative acute care hospitals of all sizes, includingtransplant centers. The U.S. data is published twice a year and the Europeandata is published once a year.
About AMR
AMR (http://www.AMR-data.com) serves the market intelligence needs of thepharmaceutical and diagnostic imaging industries. Research includes clinicalinpatient databases that directly link anti-infective drug withindication/procedure, formulary and stocking status tracking studies, drugpurchasing audits and diagnostic imaging procedure volume/contrast media usageaudits. AMR is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry. Clients rely on this analysis and data to make informeddecisions. Please visit Decision Resources, Inc. athttp://www.DecisionResourcesInc.com.All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 [email protected] [email protected]
SOURCE Arlington Medical Resources
